NCT03130036Completed
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Diet Intervention
Source: ClinicalTrials.gov · Last updated 28 Jul 2025
Brief summary (registry, in English)
This is a single center imaging study that will recruit 60 participants who are enrolled in the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy for Amyloid Transformation in AD (BEAT-AD) Study protocol. This cohort of patients will receive a maximum of 3 \[11C\]Acetoacetate (AcAc)/\[18F\]Fluorodeoxyglucose (FDG) PET scans over 18 weeks as part of this supplemental trial.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 18 Apr 2017
- Start date
- 9 Jun 2015
- Primary completion date
- 19 Jun 2024
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Alzheimer disease
- NCT number
- NCT03130036
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 9 Jun 2015 to the primary completion date, 19 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of cholesterol/lipid lowering medications, anticonvulsants, drugs with potential interfering CNS effects (other than cholinesterase inhibitors or memantine), medications with significant anticholinergic activity, anti-parkinsonian medications or regular use of narcotic analgesics
Other illness
- History of a clinically significant stroke
- Sensory impairment (visual, auditory)
- Diabetes requiring medication
Other
- Untreated hypothyroidism or B12 deficiency
Who the study is looking for
- Mild cognitive impairment or subjective memory complaints
- Stable medical condition and medications
- Ability to complete baseline assessments
Age in the registry: 50 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest School of Medicine Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.